Compare GAUZ & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GAUZ | CHRS |
|---|---|---|
| Founded | 2009 | 2010 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 102.0M | 186.0M |
| IPO Year | 2024 | 2014 |
| Metric | GAUZ | CHRS |
|---|---|---|
| Price | $1.46 | $1.33 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | ★ $11.50 | $4.02 |
| AVG Volume (30 Days) | 437.0K | ★ 861.2K |
| Earning Date | 03-11-2026 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 1.34 |
| Revenue | $96,810,000.00 | ★ $277,728,000.00 |
| Revenue This Year | $22.59 | N/A |
| Revenue Next Year | $47.83 | $67.31 |
| P/E Ratio | ★ N/A | $2.53 |
| Revenue Growth | 7.87 | ★ 152.07 |
| 52 Week Low | $0.95 | $0.71 |
| 52 Week High | $13.00 | $1.89 |
| Indicator | GAUZ | CHRS |
|---|---|---|
| Relative Strength Index (RSI) | 42.93 | 48.49 |
| Support Level | $0.98 | $1.30 |
| Resistance Level | $1.57 | $1.43 |
| Average True Range (ATR) | 0.26 | 0.08 |
| MACD | 0.13 | 0.01 |
| Stochastic Oscillator | 64.23 | 43.75 |
Gauzy Ltd is a fully integrated light and vision control company. Its products include suspended particle device and liquid crystal materials for smart glass applications and AI-powered driver assistance systems, or ADAS, solutions including camera monitoring systems. The company's operating segments are Architecture, Automotive, Safety tech, and Aeronautics. Maximum revenue is generated from its Safety tech segment, which focuses on sales of driver assistance systems for buses, coaches, recreational vehicles, and specific vehicles, such as camera and motion sensor systems, smart mirrors, and safety doors. Geographically, it derives maximum revenue from other European countries (excluding France), followed by the United States, France, Asia, Israel, and other regions.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.